TY - JOUR T1 - Impact of Acridine Orange in Patients With Local Recurrent Soft Tissue Sarcoma JF - In Vivo JO - In Vivo SP - 2745 LP - 2750 DO - 10.21873/invivo.12097 VL - 34 IS - 5 AU - HIROYUKI TSUCHIE AU - MAKOTO EMORI AU - NAOHISA MIYAKOSHI AU - KYOJI OKADA AU - HIROYUKI NAGASAWA AU - YASUTAKA MURAHASHI AU - EMI MIZUSHIMA AU - JUNYA SHIMIZU AU - TOSHIHIKO YAMASHITA AU - YOICHI SHIMADA Y1 - 2020/09/01 UR - http://iv.iiarjournals.org/content/34/5/2745.abstract N2 - Background/Aim: Local recurrence in soft tissue sarcoma (STS) is a risk factor of worse prognosis. Although a few studies have shown that adjuvant therapy with acridine orange (AO) is effective for local control of primary STS, there have been no reports examining its effectiveness for local recurrence. Patients and Methods: This retrospective study included 36 patients with first local recurrence of STS. Of them, 23 patients received wide excision without AO therapy (Wide group); the other 13 patients received marginal excision with AO therapy (AO group). We compared re-recurrence rates between these two groups. Results: The total re-recurrence rate was 43.5% in the Wide group and 46.2% in the AO group. There was no significant difference in local re-recurrence-free survival and overall survival between the two groups. Conclusion: Adjuvant AO therapy combined with a marginal excision suppresses local re-recurrence rates of individuals with local STS recurrence. ER -